Two new sites will help with mass testing needs. Photo by Getty Images

With the omicron variant showing no signs of slowing locally or nationally, the City of Houston’s health department has partnered with a major company to open two mega COVID-19 testing sites this week, both opening on Thursday, January 6.

Those near Greater Houston can look for a new mega testing site at the former Dave & Busters at 6010 Richmond Ave. Opened in partnership with Xpress COVID Testing, this new site will accommodate approximately 1,000 tests, per an announcement. January hours of operation are 9 am to 3:30 pm Mondays through Saturdays; appointments are not required.

Those outside Greater Houston to the north can look for a new site at the Kingwood Community Center (4102 Rustic Woods Dr.); its daily capacity is approximately 800 tests. January hours here are 9 am to 3:30 pm Mondays through Saturdays’ appointments are not required.

Meantime, existing mega testing sites are operating at the following locations:

Butler Stadium (13755 S Main St).
Hours are 8 am to 4 pm Mondays through Saturdays with no appointment required.

Delmar Stadium (2020 Mangum Rd.)
Hours are 8 am to 6 pm daily; appointments are required and can be made at appointments via Curative.com or by calling 1-888-702-9042.

Minute Maid Park
Minute Maid Park (Lot C, 510 St. Emanuel St.)
Hours are 8 am to 5 pm on Saturdays, Mondays, Tuesdays, Wednesdays; noon to 8 pm on Thursdays and Fridays. Appointments are required at mycovidappoitment.com or by calling 833-213-0643.

More testing sites, schedules, and appointment information are available at HoustonHealth.org or by calling 832-393-4220.

“Every Houstonian deserves to have access to testing, especially those in our most vulnerable communities,” said Mayor Sylvester Turner in a statement. “As we continue to navigate this crisis, I ask Houstonians to keep each other safe by getting tested, vaccinated, and boosted. We need everyone doing their part to remain healthy and slow the virus from spreading in their homes and places of employment and houses of worship.”

------

This article originally ran on CultureMap.

The new mega-site opens December 29. valentinrussanov/Getty Images

City of Houston announces massive new drive-through COVID testing site

new to hou

With COVID/omicron cases on the rise and Houston preparing for New Year’s Eve celebrations and travel, the City of Houston is expanding access to testing with a new drive-through mega site this week.

The site, which comes via the Houston Health Department and Curative, is located at Delmar Stadium, 2020 Mangum Rd., and opens 9 am Wednesday, December 29. Hours of operation run 8 am to 6 pm; the site promises to handle some 1,000 daily tests, according to a press release. Appointments are required at Curative.com or by calling 1-888-702-9042.

Importantly, the mega-site will be closed December 31 and January 1, 2022.

This means that at full capacity, the department’s network of Curative, United Memorial Medical Center, and multi-service center sites can provide approximately 27,000 daily tests.

Those interested can still visit HoustonHealth.org or call 832-393-4220 to find nearby free health department-affiliated testing sites and schedules.

Current Centers for Disease Control recommendations dictate that those who have symptoms and anyone who had close contact (within 6 feet for a total of 15 minutes or more over a 24-hour period) with someone with confirmed COVID-19 should test for infection.

Testing and vaccination at health department-affiliated sites is free, and does not require proof of residency, citizenship, or insurance.

“As Omicron cases surge in Houston and across the country, I applaud people for getting tested before traveling, gathering with loved ones or returning to work,” said Mayor Sylvester Turner in a statement. “Testing and vaccination will help slow the virus spread and save lives. The increased demand for testing has led to longer than usual lines and wait times for some. The new site will help meet the demand and expand capacity for testing.”

------

This article originally ran on CultureMap.

Luminostics, which was founded out of a lab at UH, received NIH grant to produce its COVID-19 rapid antigen test. Photo courtesy of Luminostics

University of Houston spinout's smartphone COVID-19 test to head to market

Pandemic innovation

A Silicon Valley startup with Houston roots is helping tackle the COVID-19 pandemic with its smartphone-based coronavirus test.

Milpitas, California-based Luminostics, a University of Houston spinout, is producing millions of its Clip COVID Rapid Antigen Test for U.S. consumers after receiving emergency authorization for the product in December. The emergency approval closely followed the National Institutes of Health awarding a $26.1 million contract to Luminostics to speed up development of the coronavirus test. According to a news release from UH, Luminostics is working on an affordable next generation hardware system to reach the mass over-the-counter market at scale.

Chemical engineers and UH alumni Bala Raja, the CEO, and Andrew Paterson, the chief technology officer, began forming their company in the UH lab of Richard Willson, a professor of chemical and biomolecular engineering and professor of biochemical and biophysical sciences.

The technology developed in the UH lab aims to equip consumers with rapid self-diagnostic tests for the flu, HIV, herpes, and other conditions by detecting the presence of bacteria, viruses, small molecules, hormones, and proteins. But Raja and Paterson put that strategy on hold last year and pivoted to re-engineering their technology for COVID-19 testing. The result: the Clip COVID Rapid Antigen Test.

"When we realized that COVID wasn't just a bad flu and that it was actually gonna go crazy and affect as many people as it has, we decided that everything we've done could be very quickly repurposed to make two different tests," Raja told Inc. magazine in April.

UH alumni Andrew Paterson and Bala Raja are co-founders of Luminostics. Photo via UH.edu

As UH explains, the Clip COVID test relies on a nasal swab, a smartphone clip, and glow-in-the-dark nanoparticles to detect a coronavirus infection within 30 minutes. In the phone, an image processor measures the intensity of the luminescence signal. If the signal is strong enough, the result is positive. If it's weak, the result is negative.

"We live in a world where you can have all your basic necessities delivered to your home through an app, and yet this pandemic has exposed how far behind the diagnostics industry lags compared to consumer technology and the convenience economy," Paterson tells UH.

Funding from the National Institutes of Health, venture capital firm Khosla Ventures, investment firm Lynette Capital, and startup accelerator Y Combinator has helped support the Clip COVID Rapid Antigen Test. The startup entered the Y Combinator program in 2016, a year after Raja and Paterson established Luminostics.

In April 2020, French pharmaceutical giant Sanofi said it was exploring a collaboration with Luminostics on the COVID-19 test.

"The diagnostics industry is saturated with products that cater to big, centralized labs or testing in the doctor's office," Paterson says. "There are many applications where it does make sense to do testing in a centralized lab, but there are dozens of other applications where there should be home-tests and there are not, because few companies have tried to take on the technical and regulatory challenges with developing home-testing."

A Houston entrepreneur created a free smartphone app to easily track and share COVID-19 testing results. Photo courtesy of SafeFun

Houston tech-turned-hospitality entrepreneur launches global health passport

there's an app for that

The pandemic brought Houston hospitality entrepreneur Carson Hager — a self-described "recovering programmer" — back to his roots in an attempt to help people gather together once more.

After 20 years in the tech world — he sold his consumer-grade commercial software company Cynergy Systems to KPMG in 2014 —Hager founded the Hospitable Viking, known for popular local bars like Rosemont in Montrose and Cherry downtown.

"It gives me some chaos," he says of his new industry. "It's something to do that's a very different challenge."

But the pandemic added a new challenge and even more chaos in his industry. As restrictions were put in place in the spring of 2020 and many (including Hager himself) didn't feel comfortable dining and drinking in public, he watched as many in his industry lost their jobs, businesses, and sense of community.

"I live in restaurants and bars and I wouldn't have gone anywhere at that point," Hager says. "I was thinking, what's it going to take for people to be able to feel comfortable to go back out again and go out to bars and restaurants, gyms, salons, club, etcetera."

In April 2020, he decided to act. And with the help of a few programmer friends pulling long hours for about 100 days straight, Hager created SafeFun, a Houston-based digital health passport that allows users to voluntarily and easily share COVID-19 test results and information.

The free app extracts and analyzes PDF test results from a variety of COVID-19 tests including molecular/diagnostic, antigen and antibody tests. SafeFun then validates the test against records from 100 partnering testing centers, including the likes of Walgreens, CVS, and Walmart, to ensure that the results are credible and summarizes the information for users to easily share through the app or in person.

After completing the build out in September 2020, Hager and his small team of four approached various city governments with the hopes of having them come on board as partners and support using the app for business purposes. However, what they found was that users were more interested in using SafeFun for personal reasons.

After a few more weeks of programming, Hager and team released the consumer-facing version in late 2020. Currently SafeFun has about 12,000 users around the world, according to Hager. Today it's mainly used ahead of a small gathering with friends, when visiting family, or to date.

SafeFun also has the capability to process and analyze proof of vaccine and other tests for infectious diseases. However, the current road block in the COVID realm is that in the U.S. most vaccine providers do not provide digital for PDF documentation.

Still, Hager envisions various potential uses for SafeFun in the future: for cruises, air travel, and even STD testing. Or, as Hager says, "God forbid, future pandemics."

Results are generally ready within 30 minutes. Photo courtesy of CVS Health

4 Houston-area CVS locations now offering free COVID-19 rapid tests

COVID-19 NEWS

Flu season and cedar fever compounded with the ongoing COVID-19 pandemic is likely to make for a worrisome winter. In an effort to make testing for the novel coronavirus more accessible, CVS is launching rapid-result tests in 21 stores across the state, including four in Houston.

The Rhode Island-based health company announced its COVID-19 testing expansion on October 28, adding that it hopes to offer the service at 1,000 clinics nationwide by the end of the year.

In the Greater Houston area, COVID-19 rapid-result tests are available at the following CVS stores beginning this week:

  • 1410 Crabb River Rd. in Richmond
  • 3505 Center St. in Deer Park
  • 2232 Repsdorph Rd. in Seabrook
  • 23865 FM 1314 in Porter

Test results are usually available within 30 minutes. Rapid-result COVID-19 tests are available at no cost to patients who meet Centers for Disease Control and Prevention criteria, for those with private insurance, or those insured by the U.S. Department of Health and Human Services, notes a release. Read more about testing costs here.

Patients must register in advance at CVS.com in order to obtain a rapid-result test. Tests are also available for patients ages 12-17, but they must have a parent or guardian fill out the testing information. Children under 15 must be accompanied by an adult to the testing site.

Once at the site, patients should remain in their vehicle and proceed to a designated site located in the parking lot. In rare occasions, the test will take place inside the store, so follow signage and instructions.

"Access to rapid-result tests enables us to help minimize community spread of COVID-19 by being able to more quickly identify active COVID-19 infection," says Dr. David Fairchild, chief medical officer at MinuteClinic, in a news release. "In addition, we can test and treat symptomatic patients who test negative for COVID-19 for seasonal illnesses such as flu or strep and provide appropriate treatment and care."

Earlier this year, CVS expanded its COVID-19 response with drive-thru service in 33 states across the U.S., including Texas. The company's latest offering comes amid a nationwide spike in coronavirus cases, including 500,000 new cases in the last week alone. As of October 26, Texas had more than 874,000 confirmed cases and 17,595 deaths.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space taps solar array developer for first space station module

space contract

Houston-based Axiom Space is making progress on developing its commercial space station.

The company awarded Florida-based Redwire Corporation a contract to develop and deliver roll-out solar array (ROSA) wings to power the Axiom Payload Power Thermal Module (AxPPTM), which will be the first module for the new space station.

AxPPTM will initially attach to the International Space Station. AxPPTM will later separate from the ISS and rendezvous with Axiom’s Habitat 1 (AxH1) on orbit. Eventually, an airlock, Habitat 2 (AxH2) and finally the Research and Manufacturing Facility (AxRMF) will be added to the first two Axiom modules.

AxPPTM is anticipated to launch toward the end of 2027. The two-module station (AxPPTM and AxH1) is expected to be operational as a free-flying station by 2028, and the full four-module station around 2030.

The modules will be integrated and assembled at Axiom Space’s Assembly and Integration facility, making them the first human-rated spacecraft built in Houston.

Redwire’s ROSA technology was originally developed for the ISS, according to Space News. It has yielded a 100 percent success rate on on-orbit performance. The technology has also been used on NASA’s Double Asteroid Redirection Test mission, the Maxar-built Power and Propulsion Element for the Artemis Lunar Gateway and Thales Alenia Space’s Space Inspire satellites.

“As a market leader for space power solutions, Redwire is proud to be selected as a strategic supplier to deliver ROSAs for Axiom Space’s first space station module,” Mike Gold, Redwire president of civil and international space, said in a news release. “As NASA and industry take the next steps to build out commercial space stations to maintain U.S. leadership in low-Earth orbit, Redwire continues to be the partner of choice, enabling critical capabilities to ensure on-orbit success.”

Greentown Houston to add new AI lab for energy startups

AI partnership

Greentown Labs has partnered with Shoreless to launch an AI lab within its Houston climatetech incubator.

"Climatetech and energy startups are transforming industries, and AI is a critical tool in that journey," Lawson Gow, Greentown's Head of Houston, said in a news release. "We're excited to bring this new offering to our entrepreneurs and corporate partners to enhance the way they think about reducing costs and emissions across the value chain."

Shoreless, a Houston-based company that enables AI adoption for enterprise systems, will support startups developing solutions for supply-chain optimization and decarbonization. They will offer Greentown members climate sprint sessions that will deliver AI-driven insights to assist companies in reducing Scope 3 emissions, driving new revenue streams and lowering expenses. Additionally, the lab will help companies test their ideas before attempting to scale them globally.

"The future of climatetech is intertwined with the future of AI," Ken Myers, Founder and CEO of Shoreless, said in a news release. "By launching this AI lab with Greentown Labs, we are creating a collaborative ecosystem where innovation can flourish. Our agentic AI is designed to help companies make a real difference, and we are excited to see the groundbreaking solutions that will emerge from this partnership."

Greentown and Shoreless will collaborate on workshops that address industry needs for technical teams, and Shoreless will also work to provide engagement opportunities and tailored workshops for Greentown’s startups and residents. Interested companies can inquire here.

Recently, Greentown Labs also partnered with Los Angeles-based software development firm Nominal to launch the new Industrial Center of Excellence at Greentown's Houston incubator. It also announced a partnership with Houston-based EnergyTech Nexus, which will also open an investor lounge on-site last month. Read more here.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston medical institutions launch $6M kidney research incubator

NIH funding

Institutions within Houston’s Texas Medical Center have launched the Houston Area Incubator for Kidney, Urologic and Hematologic Research Training (HAI-KUH) program. The incubator will be backed by $6.25 million over five years from the National Institutes of Health and aims to create a training pipeline for researchers.

HAI-KUH will include 58 investigators from Baylor College of Medicine, Texas Children’s Hospital, the University of Texas Health Science Center at Houston, University of Houston, Houston Methodist Research Institute, MD Anderson Cancer Center, Rice University and Texas A&M University Institute of Biosciences and Technology. The program will fund six predoctoral students and six postdoctoral associates. Trainees will receive support in scientific research, professional development and networking.

According to the organizations, Houston has a high burden of kidney diseases, hypertension, sickle cell disease and other nonmalignant hematologic conditions. HAI-KUH will work to improve the health of patients by building a strong scientific workforce that leverages the team's biomedical research resources to develop research skills of students and trainees and prepare them for sustained and impactful careers. The funding comes through the National Institute of Diabetes and Digestive and Kidney Diseases.

The principal investigators of the project include Dr. Alison Bertuch, professor of pediatric oncology and molecular and human genetics at BCM; Peter Doris, professor and director of the Institute of Molecular Medicine Center for Human Genetics at UT Health; and Margaret Goodell, professor and chair of the Department of Molecular and Cellular Biology at Baylor.

“This new award provides unique collaborative training experiences that extend beyond the outstanding kidney, urology, and hematology research going on in the Texas Medical Center,” Doris said in a news release. “In conceiving this award, the National Institute of Diabetes and Digestive and Kidney Diseases envisioned trainee development across the full spectrum of skills required for professional success.”

Jeffrey Rimer, a professor of Chemical Engineering, is a core investigator on the project and program director at UH. Rimer is known for his breakthroughs in using innovative methods in control crystals to help treat malaria and kidney stones. Other co-investigators include Dr. Wolfgang Winkelmeyer (Baylor), Oleh Pochynyuk (UTHealth), Dr. Rose Khavari (Houston Methodist) and Pamela Wenzel (UT Health).

“This new NIH-sponsored training program will enable us to recruit talented students and postdocs to work on these challenging areas of research,” Rimer added in a release.